



## Edgar Filing: SANOFI-AVENTIS - Form 6-K

On February 28, 2006, sanofi-aventis issued the press releases attached hereto as Exhibit 99.1 and 99.2, which are incorporated herein by reference.

### Exhibit List

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release, dated February 28, 2006, announcing the availability in the United States of Apidra, a new rapid-acting insulin analog.
Exhibit 99.2	Press Release, dated February 28, 2006, announcing the rescheduling of the trial date in the United States Plavix litigation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 1, 2006

SANOFI-AVENTIS

By: /s/ Arthur Muratyan  
Name: Arthur Muratyan  
Title: Vice President  
Corporate Law

**Exhibit Index**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release, dated February 28, 2006, announcing the availability in the United States of Apidra, a new rapid-acting insulin analog.
Exhibit 99.2	Press Release, dated February 28, 2006, announcing the rescheduling of the trial date in the United States Plavix litigation.